About Eikon Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://eikontx.com/
Frequently Asked Questions
What is the 52-week range for EIKN?
The 52-week high is $17.4 and the 52-week low is $7.4.
What is the P/E ratio for EIKN?
The P/E ratio data is currently unavailable.
What is the dividend yield for EIKN?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -119.66%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
P/B ratio data is currently unavailable.
Analyst Recommendation Trends
Wall Street analyst consensus for EIKN over the last few months:
Latest EIKN News
Alpha Buying: Follow the Money From NVIDIA and Merck
Wall Street loves a good upgrade, especially when the stock has already doubled and the analyst can explain why everyone should have owned it six months ago. One place I look for ideas is the investment portfolios of
Eikon Therapeutics, Inc. (EIKN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Eikon Therapeutics, Inc. (EIKN) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 4:05 PM EDTCompany ParticipantsRoger Perlmutter -...
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ching-Pin (“CP”) Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer. Dr. Chang is a physician-scientist and accomplished research leader with more than two decades of experience spanning academic medicin
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-03 | Column Group IV GP, LP | +89,200 | $11.5588 | $1,031,045 |
| 2026-03-02 | Klobuchar Michael A | +87,157 | - | - |
| 2026-03-02 | Thorner Benjamin Bruno | +67,044 | - | - |
| 2026-03-02 | Bowie Alfred Lloyd Jr. | +67,044 | - | - |
| 2026-03-02 | Huffines Robert Luther | +25,873 | - | - |
| 2026-03-02 | Baynes Roy D. | +134,088 | - | - |
| 2026-03-02 | PERLMUTTER ROGER M | +268,176 | - | - |
| 2026-03-02 | FRAZIER KENNETH C | +25,873 | - | - |